FIGURE 9.

Comparison of β7 internalization after treatment with vedolizumab and etrolizumab in vitro. (A) Internalization of β7 on CD4⁺ T and CD19⁺ B cells from the peripheral blood of human donors. Representative dot plots indicating the percentage of β7⁺ cells upon treatment with etrolizumab or vedolizumab at 4 or 37°C as indicated. (B) Quantification of β7⁺ internalization (decrease of surface β7 expression related to expression observed after treatment at 4°C) in T and B cell subsets treated with etrolizumab or vedolizumab as indicated. Memory cells were defined as CD45RA^-. All analyses were performed on β7^high cells (n = 5 donors). ETZ, etrolizumab; VDZ, vedolizumab; n = 10. ^∗∗∗p < 0.001.